Agendia Co-Founder Awarded EU Prize for Women Innovators

Publication Name: Press Release

Laura van ‘t Veer, Ph.D., Honored as Inventor of MammaPrint Breast Cancer Test      IRVINE, CA and AMSTERDAM, March, 10, 2014 – Agendia co-founder Laura van ‘t Veer, Ph.D., has been awarded a 2014 European Union Prize for Women … Continued

Agendia Announces Presentation of Data Highlighting Symphony Suite of Genomic tests (MammaPrint, BluePrint, and TargetPrint) at San Antonio Breast Cancer Symposium

Publication Name: Press Release

Ten Scientific Posters Document Study Results on Second-Generation Symphony Suite, Containing Multi-Gene Signatures to Provide Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS, December 9, 2013 – New breast cancer research incorporating  the SymphonyTM suite of genomic tests (MammaPrint®, BluePrint® … Continued

Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions

Publication Name: Press Release

Important Role of Molecular Subtyping in Determining the Need for Chemotherapy also Cited IRVINE, CA, and AMSTERDAM, THE NETHERLANDS, September 9, 2013 – Agendia, a leader in molecular cancer diagnostics, today announced that multiple established international breast cancer treatment guidelines … Continued